News
)
15 November 2022
Successful participation of VIVEbiotech in international events in 2022
VIVEbiotech has successfully participated in 7 international events during 2023.
)
21 June 2022
VIVEbiotech continues the expansion of its lentiviral vector manufacturing capabilities to address the viral vector bottleneck
VIVEbiotech, a gene transfer technologies Contract Development and Manufacturing Organization (CDMO) developing and GMP manufacturing lentiviral vectors, today announces its Good Manufacturing Practice (GMP)-accredited new facility is now fully operational after receiving the renewal of its GMP accreditation for a further three years.
)
4 May 2022
Interview with Natalia Elizalde in The Medicine Maker
The Business Development Director of VIVEbiotech Dr. Natalia Elizalde was interviewed by The Medicine Maker on the challenges of lentiviral vector manufacture/use.
)
2 May 2022
Gurutz Linazaroso, the CEO of VIVEbiotech, in the Medicine Maker Power List 2022
The CEO of VIVEbiotech, Dr. Gurutz Linazasoro, is part of the prestigious The Medicine Maker Power List
Destacadas
)
February 11, 2025
Celebrating women in science: honoring talent and innovation at VIVEbiotech)
February 4, 2025
VIVEbiotech joins the fight on World Cancer Day)
January 23, 2025
VIVEbiotech wins the CMO/CDMO of the Year Award at the Advanced Therapies Awards)
January 21, 2025
VIVEbiotech Shines at Advanced Therapies Week in Dallas)
January 15, 2025
VIVEbiotech named finalist for CMO/CDMO of the Year at Advanced Therapies Awards)
January 8, 2025
VIVEbiotech’s Expertise Highlighted in Drug Discovery World’s 2025 Predictions)
December 20, 2024
Merry Christmas and Happy New Year from our extraordinary team)
December 16, 2024
VIVEbiotech will be exhibiting at the Advanced Therapies Week in Dallas)
December 4, 2024
VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities)
October 25, 2024
VIVEbiotech publishes new research paper